Catalyst Brief

← Calendar

Readoutin 14d

Dr. Falk Pharma GmbH — Budesonide

Phase 3 primary completion: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE.

Date
Dec 2026
Type
Readout
Indication
Eosinophilic Esophagitis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.